ERBB2 and breast cancer: The randomized, open-label, phase III trial OlympiAD compared Olaparib with a treatment of the physician’s choice (TPC: capecitabine, vinorelbine or eribulin) in patients with a gBRCA PV and HER2-negative metastatic BC [55].